Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 4
Submit an article Journal homepage
185
Views
25
CrossRef citations to date
0
Altmetric
Review

The therapeutic potential of cannabis in multiple sclerosis

David Baker Department of Neuroinflammation, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, UK
&
Gareth Pryce Department of Neuroinflammation, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, UK
Pages 561-567 | Published online: 02 Mar 2005

Bibliography

  • COMPSTON A, COLES A: Multiple sclerosis. Lancet (2002) 359:1221–1231.
  • •Chapters review many aspects of MS, including genetics, demographics and treatments.
  • CONSROE P, MUSTY R, REIN J, TILLERY W, PERTWEE R: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur: Neurol (1997) 38:44–48.
  • •Survey of perceived effects of cannabis smoking on MS signs.
  • SCHNELLE M, GROTENHERMEN F, REIF M, GORTER RW: Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forsch Komplementanned (1999) 6\(Suppl. 3):28–36.
  • •Survey of perceived indications for cannabis use.
  • PERTWEE RG: Cannabinoids and multiple sclerosis. Phannacol Ther: (2002) 95:165–174.
  • •Review of all surveys, case reports and small scale studies of CBs used in MS up to 2002.
  • WILLIAMSON EM, EVANS FJ: Cannabinoids in clinical practice. Drugs (2000) 60:1303–1314.
  • •Review of some activities of CBs in cannabis.
  • MECHOULAM R, HANU L: The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res. Manag. (2001) 6:67–73.
  • KNOLLER N, LEVI L, SHOSHAN I et al.: Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, Phase II clinical trial. Crit. Care Med. (2002) 30:548–554.
  • GROTENHERMEN F: Some practice- relevant aspects of the pharmacokinetics of THC. Forsch Komplementanned (1999) 6\(Suppl. 3):37–39.
  • •Some pharmokinetics of cannabis.
  • KILLESTEIN J, HOOGERVORST EL, REIF M et al.: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology(2002) 58(9):1404–1407.
  • VANEY C, JOBIN P, TSCHOPP F, HEINZEL M, SCHNELLE M: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis. International Cannabinoid Research Society: 2002 Symposium on the Cannabinoids, Burlington, Vermont, USA (2002):57.
  • FOX P, THOMPSON A, ZAJICEK J: A multicentre randomised controlled trial of cannabinoids in multiple sclerosis.' Neurol Sci. (2001) 187:S453.
  • BRADY CM, DAS GUPTA R, WISEMAN 0J, DALTON CM, BERKLEY KJ, FOWLER CJ: The effects of cannabis based medicinal extracts on lower urinary tract dysfunction in advanced multiple sclerosis: preliminary results. Nemo]. Neurosurg. Psych. (2002) 72:139.
  • NOTCUTT W, PRICE M, SANSOM C, SIMMONS S, PHILLIPS C: Medicinal cannabis extract in chronic pain: Overall results of 29 "N of 1" studies (CBME-nternational Cannabinoid Research Society: 2002 Symposium on the Cannabinoids, Burlington, Vermont, USA (2002):55.
  • ROBSON PJ, WADE DT, MAKELA PM, HOUSE H: Cannabis medicinal extracts (CME), including cannabidiol, alleviated neurogenic systems in patients with multiple sclerosis and spinal cord injury. International Cannabinoid Research Society: 2002 Symposium on the Cannabinoids, Burlington, Vermont, USA (2002):56.
  • BREIVOGEL CS, CHILDERS SR The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis.(1998) 5:417–431.
  • •Review of CB receptors. This whole issue is dedicated to CB biology.
  • LUTZ B: Molecular biology of cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:123–142.
  • •Review of CB receptor structure and function. This whole issue is dedicated to CB biology.
  • MCALLISTER SD, GLASS M: CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:161–171.
  • PERTWEE RG: Pharmacology of cannabinoid receptor ligands. Curr: Med. Chem. (1999) 6:635–664.
  • •Review of receptor affmity of many pharmacological CB-binding compounds.
  • REGGIO PH: Endocannabinoid structure- activity relationships for interaction at the cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Adds (2002) 66:143–160.
  • •Review of endocannabinoids.
  • SUGIURA T, KOBAYASHI Y, OKA S WAKU K: Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:173–192.
  • •Review of endocannabinoid formation and degradation.
  • DEUTSCH DG, UEDA N, YAMAMOTO S: The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:201–210.
  • •Review of endocannabinoid degrading enzyme.
  • CRAVATT BE DEMAREST K, PATRICELLI MP et al.: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA (2001) 98:9371–9376.
  • •Demonstration of regulation of anandamide by FAAH using a knockout system.
  • LICHTMAN AH, HAWKINS EG, GRIFFIN G, CRAVATT BF: Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. Pharmacol Exp. Ther. (2002) 302:73–79.
  • •Evidence for a novel enzyme degrading 2-AG.
  • DINH TP, CARPENTER D, LESLIE FM et al.: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad Sci. USA (2002) 99:10819–10824.
  • WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296:678–682.
  • •Review of control synaptic neurotransmission.
  • PERTWEE RG, ROSS RA: Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatg Acids (2002) 66:101–121.
  • WALKER J, HUANG S: Cannabinoid analgesia. Pharmacol Ther (2002) 95:127–135.
  • •Review of the use of CBs in pain. This whole issue is dedicated to CB biology.
  • DEGENHARDTL, HALL W: Cannabis and psychosis. Curc Psychiatry Rep. (2002) 4:191–196.
  • •Review of evidence of cannabis-induced psychosis.
  • VAN OS J, BAK M, HANSSEN M, BIJL RV, DE GRAAF R, VERDOUX H: Cannabis use and psychosis: a longitudinal population-based study. Am. I Epideiniol (2002) 156:319–327.
  • •New evidence of cannabis-induced psychosis.
  • MONORY K, TZAVARA ET, LEXIME J et al.: Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochein. Biophys. Res. Commun. (2002) 292:231–235.
  • BROOKS JW, PRYCE G, BISOGNO T et al.: Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. Pharmacol (2002) 439:83–92.
  • •Evidence for a novel non-CB1 receptor controlling experimental spasticity.
  • RICE ASC, FARQUHAR-SMITH WP, NAGY I: Endocannabinoids and pain: spinal and peripheral analgesis in inflammation and neuropathy. Prostaglandins Leukot. Essen] Fatn Acids. (2002) 66:243–256.
  • BAKER D, PRYCE G, CROXFORD JL et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84–87.
  • •First objective experimental evidence that CBs control spasticity.
  • BAKER D, PRYCE G, CROXFORD JL et al.: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB (2001) 15:300–302.
  • •Experimental evidence that demonstrates endocannabinoid tone in control of spasticity.
  • STEINMAN L: Immunotherapy of multiple sclerosis: the end of the beginning. Cuir. Opin. Immunol (2001) 13:597–600.
  • •Review of some treatments in MS.
  • KLEIN TW, NEWTON CA, FRIEDMAN H: Cannabinoids and the immune system. Pain Res. Manag. (2001) 6:95–101.
  • •Review of CB effects on the immune system and cytokine secretion.
  • PAROLARO D, MASSI P, RUBINO T, MONTI E: Endocannabinoids in the immune system and cancer. Prostaglandins Leukot. Essen] Fatn "Acids. (2002) 66:319–332.
  • •Review of CB effects on the irmrtune system and cytokine secretion.
  • MCKALLIP RJ, LOMBARD C, MARTIN BR, NAGARKATTI M, NAGARKATTI PS: Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. Pharmacol Exp. Ther. (2002) 302:451–465.
  • LYMAN WD, SONETT JR, BROSNAN CE ELKIN R, BORNSTEIN MB: Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. Neuroimmunol (1989) 23:73–81.
  • •Irnmunosuppression in an experimental MS model.
  • WIRGUIN I, MECHOULAM R, BREUER A, SCHEZEN E, VVEIDENFELD J, BRENNER T: Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1994) 28:209–214.
  • •Irnmunosuppression in an experimental MS model.
  • DI MARZO V, GOPARAJU SK, WANG L et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410:822–825.
  • MATARESE G, DI GIACOMO A, SANNA V et al.: Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. Immunol (2001) 166:5909–5916.
  • NAHAS GG, SUCIU-FOCA N, ARMAND JP, MORISHIMA A: Inhibition of cellular mediated immunity in marihuana smokers. Science (1974) 183:419–420.
  • BJARTMAR C, TRAPP BD: Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol (2001) 14:271–278.
  • •Review on neurodegeneration in MS. This occurs early in disease and correlates with the development of permanent disability.
  • COLES AJ, WING MG, MOLYNEUX P et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Nemo] (1999) 46:296–304.
  • •Although the agent inhibited relapse rate and magnetic resonance imaging (MRI) lesions patients continued to progress.
  • WUJEK JR, BJARTMAR C, RICHER E et al.: Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. Neuropathol Exp. Nemo] (2002) 61:23–32.
  • GLASS M, DRAGUNOW M, FAULL RL: The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience (2000) 97:505–519.
  • SMITH T, GROOM A, ZHU B, TURSKI L: Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. (2000) 6:62–66.
  • WERNER P, PITT D, RAINE CS: Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Nemo]. (2001) 50(2):169–180.
  • GUZMAN M, SANCHEZ C, GALVE-ROPERH I: Cannabinoids and cell fate. Pharmacol Ther. (2002) 95:175–184.
  • •Review of cell fate following exposure to CBs.
  • PANIKASHVILI D, SIMEONIDOU C, BEN-SHABAT S et al.: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 413:527–531.
  • GRUNDY RI: The therapeutic potential ofthe cannabinoids in neuroprotection. Expert Opin. Investig. Drugs. (2002) 11:1365–1374.
  • •Review of CB-mediated neuroprotection.
  • PRYCE G, HANKEY D, AHMED Z, BAKER D: Cannabinoid treatment and CB1 receptor involvement in inflammatory disease in the CNS. International Cannabinoid Research Society: 2002 Symposium on the Cannabinoids, Burlington, Vermont, USA (2002):50.
  • •Evidence for role of CB 1-mediated neuroprotection in an experimental MS model.
  • DI MARZO V, DE PETROCELLIS L, FEZZA F, LIGRESTI A, BISOGNO T: Anandamide receptors. Prostaglandins Leukot. Essen] Fatn Acids (2002) 66:377–391.
  • •Review of the ability of anandarnide to mediate biological effects via vanilloid receptors.
  • LEVER IJ, MALCANGIO M: CB(1) receptor antagonist 5R141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord. Br. Pharmacol (2002) 135:21–24.
  • FOWLER CJ: Intravesical treatment of overactive bladder. Urology (2000) 55(Suppl. 5A):60–64.
  • MACCARRONE M, LORENZON T, BARI M, MELINO G, FINAZZI-AGRO A: Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. Biol. Chem. (2000) 275:31938–31945.

Websites

  • http://www.cannabis-trial.plymouth.ac.uk Cannabinoids in multiple sclerosis trial.
  • http://www.gwpharm.com GW Pharmaceuticals website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.